Advancing Long-Acting Therapeutics Across Animal Health
At Fidelis Animal Health, we are building a differentiated pipeline of long-acting therapeutics powered by our proprietary extended-release technology platform. Our approach is designed to improve outcomes, reduce handling, and elevate standards of care across both research settings and companion animal medicine.
With a commercial-stage foundation and proven technology, we are actively expanding our portfolio to address unmet needs across multiple species and clinical indications.
We are seeking partners who share our commitment to advancing animal health through innovation.
We welcome discussions with:
- Pharmaceutical and biotechnology companies
- Academic and research institutions
- Investors and strategic collaborators
If you have assets, technologies, or ideas that could benefit from our long-acting delivery platform, we invite you to connect with us.
Contact us to explore partnership opportunities and help shape the future of animal health.
Proprietary Technology – Fidelipid LAI
In partnership with Johns Hopkins University, Fidelis has developed a research platform with proprietary extended-release technology – Fidelipid LAI.
It’s proven to provide up to 72 hours of therapeutic levels (clinical analgesia) with one injection. This technology is triple patent-protected for all species, for all APIs (exception of opioids in humans).